1. Home
  2. GRFS vs DNTH Comparison

GRFS vs DNTH Comparison

Compare GRFS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$7.99

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$86.57

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRFS
DNTH
Founded
1940
2015
Country
Spain
United States
Employees
25247
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
4.6B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
GRFS
DNTH
Price
$7.99
$86.57
Analyst Decision
Hold
Strong Buy
Analyst Count
2
13
Target Price
$10.15
$121.00
AVG Volume (30 Days)
589.6K
422.6K
Earning Date
07-28-2022
05-06-2026
Dividend Yield
1.80%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,036,000.00
Revenue This Year
$4.49
N/A
Revenue Next Year
$6.42
$29.48
P/E Ratio
$18.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.39
$16.77
52 Week High
$11.14
$96.50

Technical Indicators

Market Signals
Indicator
GRFS
DNTH
Relative Strength Index (RSI) 48.45 49.95
Support Level $7.87 $82.00
Resistance Level $9.78 $90.23
Average True Range (ATR) 0.21 4.58
MACD 0.02 -0.20
Stochastic Oscillator 50.26 52.27

Price Performance

Historical Comparison
GRFS
DNTH

About GRFS Grifols S.A.

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: